Mesoblast Ltd
NASDAQ:MESO

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
NASDAQ:MESO
Watchlist
Price: 18.57 USD 1.53% Market Closed
Market Cap: 2.1B USD

MESO's latest stock split occurred on Jan 10, 2024

The company executed a 1-for-2 stock split, meaning that for every 2 shares held, investors received 1 new share.

Before the split, MESO traded at 1.04 per share. Afterward, the share price was about 1.93.

The adjusted shares began trading on Jan 10, 2024. This was the only stock split in MESO's history.

Last Splits:
Jan 10, 2024
1-for-2
Pre-Split Price
2.08 1.04
Post-Split Price
1.93
Before
After
Last Splits:
Jan 10, 2024
1-for-2

Mesoblast Ltd
Stock Splits History

MESO Stock Splits Timeline
Jan 10, 2024
Jan 10, 2024
Split 1-for-2
/0.5
Pre-Split Price
2.08 1.04
Post-Split Price
1.93
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.1377 0.1377 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.57 8.57 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 6, 2026
Itochu Corp
F:IOC0
10-for-1
x10
1060 106 EUR N/A
Load More

Mesoblast Ltd
Glance View

Market Cap
2.1B USD
Industry
Biotechnology

Mesoblast Ltd., a biotechnology company based in Australia, is navigating the frontier of regenerative medicine with its innovative approach to cell therapy. Founded in 2004, Mesoblast has carved a niche for itself by concentrating on the development and commercialization of allogeneic cellular medicines derived from mesenchymal lineage adult stem cells. These stem cells are pivotal in regenerative therapy due to their remarkable ability to differentiate, reduce inflammation, and promote tissue repair. Mesoblast harnesses this potential to address critical medical conditions, including cardiovascular diseases, spine diseases, immune-mediated diseases, and some rare pediatric conditions. By developing proprietary technology, the company aims to produce off-the-shelf therapies that can be readily available to patients, avoiding the complexities and delays often associated with personalized cellular therapies. The company’s revenue model hinges on the development of its extensive pipeline of products, with an eye towards capturing significant market opportunities across multiple therapeutic areas. Revenues are primarily anticipated from three avenues: collaborations with major pharmaceutical companies, licensing agreements, and, eventually, product sales upon regulatory approval. Mesoblast's strategic partnerships often involve substantial upfront payments, milestone payments, and royalties on the sale of licensed products. For instance, collaborations with giants like Grunenthal in Europe have fortified its research and funding capabilities. Meanwhile, Mesoblast is also committed to expanding its product commercialization capabilities to strategically manage its transition from a research-centered entity to a biopharmaceutical pioneer with marketed therapies. This dual-focused strategy aspires to deliver shareholder value while advancing the horizons of medical treatment.

MESO Intrinsic Value
14.25 USD
Overvaluation 23%
Intrinsic Value
Price
Back to Top